Adverse Event Reporting - Mpje

1. Identify the correct reporting choice when a patient dies and a medication is suspected to have contributed.

   Report immediately via MedWatch (serious adverse event: death). Death qualifies as a serious adverse event necessitating prompt reporting to identify safety concerns.

2. Which FDA form is used by manufacturers for mandatory adverse event reporting (postmarketing) for drugs/biologics?

   Form FDA 3500A. Form 3500A is required for manufacturers to fulfill mandatory postmarketing adverse event reporting obligations to the FDA.

3. Which option best describes what to do when a patient reports a serious adverse event from an OTC product?

   Submit a MedWatch report (FDA 3500) and advise medical evaluation. Serious adverse events from OTC products warrant voluntary reporting and patient guidance for evaluation.

4. Which option best describes how HIPAA affects submitting an FDA adverse event report by a pharmacist?

   Permitted as a public health activity; disclose minimum necessary. HIPAA permits disclosures for public health purposes like FDA adverse event reporting without authorization.

5. What is the FDA program for voluntary reporting of adverse events and product problems for drugs and devices?

   MedWatch (FDA Safety Information and Adverse Event Reporting Program). MedWatch facilitates voluntary reporting by healthcare professionals and consumers to monitor post-market safety of drugs and devices.

6. What is the correct action if you learn of an adverse event from a caregiver who is willing to be contacted by FDA?

   Use the caregiver as the identifiable reporter and include contact information. Caregivers can serve as identifiable reporters to enable valid adverse event submissions to the FDA.

7. What is the correct action when a serious adverse event occurs after a REMS medication is dispensed and administered?

   Ensure patient care, then report via MedWatch and follow REMS requirements. REMS programs require specific adverse event reporting after ensuring immediate patient care.

8. What is the best action when a patient reports an adverse event but refuses to provide any identifiers at all?

   Report if you still have an identifiable patient; otherwise insufficient core elements. Valid adverse event reports require an identifiable patient as a core element for follow-up and verification.

9. Which option is the correct reporting pathway for a medication error that reached the patient and caused harm?

   Report to ISMP and/or FDA MedWatch as appropriate. Reporting medication errors that cause harm helps identify systemic issues and improve patient safety practices.

10. Which option is the correct reporting pathway for a serious adverse event following an immunization?

    Submit a VAERS report. VAERS is the designated national system for reporting and analyzing adverse events following immunization.

11. Which option is the correct first priority when a severe allergic reaction occurs immediately after administration in the pharmacy?

    Provide/activate emergency care first; report afterward. Immediate patient care takes priority over reporting to ensure safety in acute emergency situations.

12. What is the name of the FDA system that collects reports of adverse events for vaccines?

    VAERS (Vaccine Adverse Event Reporting System). VAERS, co-managed by FDA and CDC, collects vaccine adverse event reports to ensure ongoing vaccine safety monitoring.

13. What is the name of the nonprofit program that collects and analyzes medication error reports in the United States?

    ISMP (Institute for Safe Medication Practices). ISMP operates a confidential reporting program to analyze errors and recommend prevention strategies nationwide.

14. What is the correct approach when reporting an adverse event potentially related to pregnancy exposure to a medication?

    Report via MedWatch and include pregnancy status and outcomes if known. Including pregnancy details in reports helps assess medication risks to maternal and fetal health.

15. Identify the minimum core elements needed for a valid postmarketing adverse event case report to a manufacturer/FDA.

    Identifiable patient, identifiable reporter, suspect product, adverse event. These four elements are required for a report to be considered valid and actionable by the FDA or manufacturers.

16. What is the FDA form number commonly used to submit a MedWatch report for an adverse event?

    Form FDA 3500. Form 3500 enables voluntary submission of adverse event reports by non-manufacturers to the FDA's MedWatch program.

17. What is the correct action if a patient reports lack of effect that could indicate therapeutic failure with a critical drug?

    Report as an adverse event/product problem via MedWatch. Lack of effect in critical drugs may signal quality issues or inefficacy requiring FDA investigation.

18. Identify the best action if you suspect a counterfeit or tampered drug after a patient experiences unexpected toxicity.

    Quarantine product and report to FDA (MedWatch/OCI) and supplier. Suspected counterfeits must be isolated and reported to protect public health and initiate investigations.

19. Identify the best action when a patient reports an adverse event but cannot recall the exact product name or strength.

    Report with best available identifiers (NDC/description) and note uncertainty. Reports with partial product details still contribute to safety surveillance despite uncertainties.

20. Identify the correct reporting concept for product quality complaints (e.g., wrong odor, particles) without patient harm.

    Report as a product problem/quality complaint (MedWatch). Quality complaints are reported to MedWatch to monitor manufacturing and prevent potential harm.

21. Identify what information is most important to document for an adverse event report besides the reaction description.

    Suspect drug, dose/route, dates, outcome, concomitant meds, reporter contact. Detailed documentation aids FDA in evaluating causality, patterns, and necessary regulatory actions.

22. Which option best describes a pharmacist's general federal obligation when learning of a serious drug adverse event?

    Report via MedWatch (voluntary for health care professionals). Federal regulations encourage voluntary reporting by pharmacists of serious drug adverse events through the MedWatch system.

23. What is the correct reporting approach when an adverse event is suspected but causality is uncertain?

    Report it; proof of causality is not required. FDA policy allows reporting based on suspicion alone to detect potential safety signals without needing proof.

24. Which option is correct if the event involves a medical device used to administer a drug (e.g., infusion pump malfunction)?

    Report to FDA (MedWatch); consider device reporting pathways as applicable. MedWatch covers device-related drug events, with potential for specific device reporting channels.

25. Which option is correct when a patient experiences harm from a compounded preparation suspected to be contaminated?

    Report to FDA (MedWatch), state board as required, and quarantine/trace lot. Suspected contamination in compounds requires reporting, quarantine, and tracing to mitigate risks.

Study these flashcards